Revance Therapeutics Inc RVNC:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/03/24 EDT
3.95quote price arrow up+0.18 (+4.77%)
Volume
1,354,247
52 week range
3.21 - 37.98
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close3.95
  • 52 Week High37.98
  • 52 Week High Date05/09/23
  • 52 Week Low3.21
  • 52 Week Low Date04/26/24

Key Stats

  • Market Cap411.652M
  • Shares Out104.22M
  • 10 Day Average Volume2.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.10
  • YTD % Change-55.06

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close3.95
  • 52 Week High37.98
  • 52 Week High Date05/09/23
  • 52 Week Low3.21
  • 52 Week Low Date04/26/24
  • Market Cap411.652M
  • Shares Out104.22M
  • 10 Day Average Volume2.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.10
  • YTD % Change-55.06

RATIOS/PROFITABILITY

  • EPS (TTM)-3.81
  • P/E (TTM)-1.04
  • Fwd P/E (NTM)-1.88
  • EBITDA (TTM)-207.032M
  • ROE (TTM)-2,096.78%
  • Revenue (TTM)234.04M
  • Gross Margin (TTM)68.23%
  • Net Margin (TTM)-138.43%
  • Debt To Equity (MRQ)-284.79%

EVENTS

  • Earnings Date05/09/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Revance Therapeutics Inc

 

Content From Our Affiliates

Profile

MORE
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar...
Angus Russell
Independent Chairman of the Board
Mark Foley
Chief Executive Officer, Director
Tobin Schilke
Chief Financial Officer
Address
1222 Demonbreun Street, Suite 2000
Nashville, TN
37203
United States

Top Peers

SYMBOLLASTCHG%CHG
PBYI
Puma Biotechnology Inc
4.86-0.10-2.02%
ME
23andMe Holding Co.
0.5023-0.0023-0.4558%
CHRS
Coherus BioSciences Inc
2.27+0.10+4.61%
PACB
Pacific Biosciences of California Inc
1.83+0.07+3.98%
AKBA
Akebia Therapeutics Inc
1.37+0.07+5.38%